ArticleBMC veterinary research2025
Alterations in mitochondrial DNA content in canine heart failure.
Article in BMC veterinary research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHeart failure is the most common lethal consequence of cardiovascular abnormalities in the dog population. In humans, the abundance of mtDNA content plays a crucial role in the pathogenesis of different types of cardiovascular diseases such as ischemic heart disease, dilated cardiomyopathy, and congestive HF. Changes in mtDNA copy number could indicate the extent of mtDNA damage, serving as a potential biomarker for mitochondrial function and a predictor of several cardiovascular disease risks in humans. However, evidence regarding the alterations in mtDNA content in canine heart failure remains poorly explored. This study aims to determine the peripheral blood mitochondrial DNA content in healthy dogs and those experiencing acute heart failure.
resultsA total of thirty client-owned dogs, aged between 5 and 15 years, were selected for the study. The dogs were categorized into two groups: a healthy group (HT, n = 15) and a heart failure group (HF, n = 15). A comprehensive evaluation was performed on all dogs, involving physical examination, thoracic radiography, and transthoracic echocardiographic assessment. Additionally, three milliliters of blood were collected for hematology, blood chemistry profiles, and mitochondrial DNA (mtDNA) analysis. The monocyte levels were found to be significantly higher in the heart failure group (HF) than in the healthy group (HT). Furthermore, parameters such as blood urea nitrogen (BUN), creatinine, vertebral heart score (VHS), and vertebral left atrial size (VLAS) showed significant elevation in the HF group (p-value < 0.05). Echocardiographic measurements, including left ventricular internal dimension at end-diastole (LVIDd), left atrium (LA), left atrial to aortic root ratio (LA/Ao), end-diastolic volume (EDV), end-systolic volume (ESV), and left ventricular mass, were also notably higher in the HF group compared to the healthy group (p-value < 0.05). Moreover, the mtDNA content was significantly higher in the HF group than in the healthy group (p-value < 0.05).
conclusionIn the context of decompensated HF, the occurrence of tissue hypoxia might instigate cellular damage, consequently resulting in the release of mtDNA. This phenomenon potentially explains the observed higher mtDNA content in the HF group in comparison to the healthy group.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.